Synopsis
Synopsis
0
JDMF
0
EU WC
0
VMF
DRUG PRODUCT COMPOSITIONS
Annual Reports
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 847.0 g/mol |
|---|---|
| Molecular Formula | C46H62N4O11 |
| XLogP3 | 6.3 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 5 |
| Exact Mass | 846.44150881 g/mol |
| Monoisotopic Mass | 846.44150881 g/mol |
| Topological Polar Surface Area | 206 A^2 |
| Heavy Atom Count | 61 |
| Formal Charge | 0 |
| Complexity | 1870 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 9 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 3 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Mycobutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
| 2 of 4 | |
|---|---|
| Drug Name | Rifabutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Lupin |
| 3 of 4 | |
|---|---|
| Drug Name | Rifabutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Lupin |
| 4 of 4 | |
|---|---|
| Drug Name | Mycobutin |
| PubMed Health | Rifabutin (By mouth) |
| Drug Classes | Antitubercular |
| Drug Label | MYCOBUTIN Capsules contain the antimycobacterial agent rifabutin, which is a semisynthetic ansamycin antibiotic derived from rifamycin S. MYCOBUTIN Capsules for oral administration contain 150 mg of rifabutin, USP, per capsule, along with the inactiv... |
| Active Ingredient | Rifabutin |
| Dosage Form | Capsule |
| Route | Oral |
| Strength | 150mg |
| Market Status | Prescription |
| Company | Pharmacia And Upjohn |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35705
Submission : 2024-02-06
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19902
Submission : 2006-10-20
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-07-20
Pay. Date : 2018-05-08
DMF Number : 29047
Submission : 2015-01-22
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Certificate Number : R0-CEP 2001-111 - Rev 01
Status : Expired
Issue Date : 2005-03-10
Type : TSE
Substance Number : 1657

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] NDC Package Code : 17337-0059
Start Marketing Date : 2014-10-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Chongqing Huapont Pharmaceutical Co., Ltd. was established in 1994 and is now located in Liangjiang New District, Chongqing. It is a national high-tech enterprise, a national innov...

About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...

About the Company : We produce Active Pharmaceutical Ingredients (APIs) providing integrated full-service capabilities. Olon’s ability to develop and manufacture Active Pharmaceutical Ingredients (...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code :
Brand Name : RIFABUTIN
Dosage Form : CAPSULE;ORAL
Dosage Strength : 150MG
Approval Date : 2014-02-24
Application Number : 90033
RX/OTC/DISCN : DISCN
RLD : No
TE Code :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : No
TE Code : AB
Brand Name : RIFABUTIN
Dosage Form : CAPSULE;ORAL
Dosage Strength : 150MG
Approval Date : 2021-12-17
Application Number : 215041
RX/OTC/DISCN : RX
RLD : No
TE Code : AB

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
RLD : Yes
TE Code : AB
Brand Name : MYCOBUTIN
Dosage Form : CAPSULE;ORAL
Dosage Strength : 150MG
Approval Date : 1992-12-23
Application Number : 50689
RX/OTC/DISCN : RX
RLD : Yes
TE Code : AB

AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN
Brand Name : TALICIA
Dosage Form : CAPSULE, DELAYED RELEASE;ORAL
Dosage Strength : 250MG;EQ 10MG BASE;12.5MG
Approval Date : 2019-11-01
Application Number : 213004
RX/OTC/DISCN : RX
RLD : Yes
TE Code :

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Generic
Registration Country : United Kingdom
Brand Name :
Dosage Form : CAPSULE
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number : 50689
Regulatory Info : Generic
Registration Country : United Kingdom

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Mycobutin
Dosage Form : Rifabutin 150Mg 30 Joined' Oral Use
Dosage Strength : 30 cps 150 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Ansatipin
Dosage Form : Capsule
Dosage Strength : 150mg
Packaging :
Approval Date : 03/12/1993
Application Number : 19931203000079
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Mycobutin
Dosage Form : Capsule
Dosage Strength : 150mg
Packaging :
Approval Date : 25/02/1994
Application Number : 52068
Regulatory Info : Allowed
Registration Country : Switzerland

Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Ansatipin
Dosage Form : Hard Capsule
Dosage Strength : 150MG
Packaging :
Approval Date : 01-12-1994
Application Number : 60228
Regulatory Info : Authorized
Registration Country : Spain

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Rifabutin \"Nordic Prime\"
Dosage Form : Hard Capsules
Dosage Strength : 150mg
Packaging :
Approval Date : 25-05-2022
Application Number : 28106727722
Regulatory Info : Prescription
Registration Country : Denmark

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Canada
Brand Name : MYCOBUTIN
Dosage Form : CAPSULE
Dosage Strength : 150MG
Packaging : 100
Approval Date :
Application Number : 2063786
Regulatory Info : Prescription
Registration Country : Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Australia
Brand Name : Mycobutin
Dosage Form : capsule
Dosage Strength : 150 mg
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Australia
Brand Name : Mycobutin
Dosage Form : capsule
Dosage Strength : 150 mg
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Mycobutin
Dosage Form : CAP
Dosage Strength : 150mg
Packaging : 30X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Capsule
Dosage Strength : 150MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Packaging :
Regulatory Info :
Dosage : Capsule
Dosage Strength : 150MG
Brand Name :
Approval Date :
Application Number :
Registration Country : China

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
60
PharmaCompass offers a list of Rifabutin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rifabutin manufacturer or Rifabutin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rifabutin manufacturer or Rifabutin supplier.
PharmaCompass also assists you with knowing the Rifabutin API Price utilized in the formulation of products. Rifabutin API Price is not always fixed or binding as the Rifabutin Price is obtained through a variety of data sources. The Rifabutin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ansamicin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ansamicin, including repackagers and relabelers. The FDA regulates Ansamicin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ansamicin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Ansamicin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Ansamicin supplier is an individual or a company that provides Ansamicin active pharmaceutical ingredient (API) or Ansamicin finished formulations upon request. The Ansamicin suppliers may include Ansamicin API manufacturers, exporters, distributors and traders.
click here to find a list of Ansamicin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ansamicin DMF (Drug Master File) is a document detailing the whole manufacturing process of Ansamicin active pharmaceutical ingredient (API) in detail. Different forms of Ansamicin DMFs exist exist since differing nations have different regulations, such as Ansamicin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ansamicin DMF submitted to regulatory agencies in the US is known as a USDMF. Ansamicin USDMF includes data on Ansamicin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ansamicin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ansamicin suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Ansamicin Drug Master File in Korea (Ansamicin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Ansamicin. The MFDS reviews the Ansamicin KDMF as part of the drug registration process and uses the information provided in the Ansamicin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Ansamicin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Ansamicin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Ansamicin suppliers with KDMF on PharmaCompass.
A Ansamicin CEP of the European Pharmacopoeia monograph is often referred to as a Ansamicin Certificate of Suitability (COS). The purpose of a Ansamicin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Ansamicin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Ansamicin to their clients by showing that a Ansamicin CEP has been issued for it. The manufacturer submits a Ansamicin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Ansamicin CEP holder for the record. Additionally, the data presented in the Ansamicin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Ansamicin DMF.
A Ansamicin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Ansamicin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Ansamicin suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Ansamicin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Ansamicin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Ansamicin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Ansamicin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Ansamicin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Ansamicin suppliers with NDC on PharmaCompass.
Ansamicin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ansamicin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ansamicin GMP manufacturer or Ansamicin GMP API supplier for your needs.
A Ansamicin CoA (Certificate of Analysis) is a formal document that attests to Ansamicin's compliance with Ansamicin specifications and serves as a tool for batch-level quality control.
Ansamicin CoA mostly includes findings from lab analyses of a specific batch. For each Ansamicin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ansamicin may be tested according to a variety of international standards, such as European Pharmacopoeia (Ansamicin EP), Ansamicin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ansamicin USP).